TNF.alpha. receptor-derived binding protein
US5633145A · kind A · utility
27Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 1993 |
| Grant date | May 27, 1997 |
| Priority date | — |
| Expiry date | May 10, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A polypeptide is provided which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF.alpha.. The ability of the polypeptide to bind TNF.alpha. means that it can be used for treating diseases mediated by TNF.alpha. activity, such as rheumatoid arthritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.